We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Using AI should speed up detection of diseases caused by genetic variants but it does not guarantee success
New rules are designed to make medicines cheaper for American seniors. But companies warn innovation will suffer
Unlike the vaccine race, there is limited funding to treat a condition that is often debilitating
Medicare’s negotiations on the cost of medicines could affect how drug research is funded globally
New model aims to reduce high development costs and increase number of drugs being tested
Antimicrobial resistance already kills millions and is projected to get worse. But there is little incentive for Big Pharma to tackle the issue
Anglo-Swedish group is latest to challenge Medicare’s new power to negotiate prices for a limited number of medicines
Shares in Swiss pharma group rally after analyst discovers data on immunotherapy medicine on website
Joint work would avoid ‘deep scars’ caused by unequal access to drugs during Covid-19
US pharmaceutical group says it wants to become the first trillion dollar healthcare company
A new study bolsters the case that semaglutide is not merely a vanity drug but has a key role to play in treating obesity
Drugs that tackle obesity, diabetes and heart disease are good for profits and the public
Shares in Danish drugmaker and US rival Eli Lilly surge to record highs after positive trial of weight-loss drug
Legal and regulatory actions are more likely to drag on earnings than negate them
Novo Nordisk and Eli Lilly accused of failing to warn patients of gastroparesis risk
Promising trial results will not end scientific debate over the disease, but they further validate pharmaceutical research
Dementia experts hail ‘watershed moment’ after trial results for donanemab antibody treatment
Move by Food and Drug Administration paves way for millions of Americans to access medicine
Trial studied patients with advanced non-small cell lung cancer
A decade ago a large part of Big Pharma gave up on one of humanity’s cruellest diseases. But then a new treatment showed promise
Successful pilot in England will be expanded to more pharma companies and include N Ireland, Scotland and Wales
New treatments have had remarkable results but there are reasons to be cautious
Large-scale study will test GSK’s jab in 26,000 people in Africa and south-east Asia
Insilico Medicine says trial of lung disease therapy is milestone for generative AI in drug development
German group aims to join companies whose fortunes have been transformed by weight loss treatments
International Edition
